All In Biotech

Drug Trial Radar · NCT06166836

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Oct 12, 2022

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
InxMed (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
Collaborators
InventisBio Co., Ltd
First posted
Dec 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.

Conditions

  • Solid Tumor

Interventions

  • D1553Drug

    D1553 orally taken,600mg twice a day

  • IN10018(Ifebemtinib)Drug

    IN10018 orally taken once daily at approximately the same time each day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase II dose (RP2D) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutationTime frame: Through study completion, approximately 3 years
  2. Objective Response Rate (ORR) of D1553 in combination with IN10018 in solid tumors with KRAS G12C mutationTime frame: Through study completion, approximately 3 years

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Hunan Cancer Hospital

    Changsha, China

  • Fujian Cancer Hospital

    Fuzhou, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, China

  • General Hospital Of Eastern Theater Command

    Nanjing, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • Xuzhou Central Hospital

    Xuzhou, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • The first Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.